Figure 1B,C show that repeated doses of R-337 monotherapy exerted almost complete protection. The mice exhibited a strong T cell response, seen as splenocyte reactivity to CT26-HER2 cells, supporting the view that the protection might, in part, be immune-mediated (Figure 1D). Remarkably, the mice developed a T cell response also against agnostic tumor antigens expressed by CT26-wt cells (Figure 1D). The antibodies response was directed primarily to HER2 (Figure 1E) and to a limited extent to the CT26-wt tumor cell antigens (trend, not statistically significant). The gene discussed is ERBB2; the disease is neoplasm.